Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event
18.11.2020 16:00:00 EET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.
The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.
ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.
NeXT Liquid Biopsy, a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.
Following are details for the Personalis presentations.
Scientific Poster Presentation
|
Poster Number |
Title & Presenter |
Dates |
||
|
40
|
Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach
|
NOV 18-19 | Online |
Following are details of an industry-sponsored symposium which will be presented at the meeting.
Satellite Symposia
|
Title |
Title & Presenter |
Dates |
||
|
Sponsored Symposia |
NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics
|
NOV 18-19 | On Demand |
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform ® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis’ services for the VA MVP, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005479/en/
Contact information
Investor Relations Contact:
Caroline Corner
investors@personalis.com
415-202-5678
Media Contact:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carrier and PHINIA Recognized with ISG Paragon Awards North America 2026 for Transformation Delivered with LTM30.9.2026 11:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced that its clients PHINIA and Carrier have been recognized at the ISG Paragon Awards North America 2026. LTM received recognition in the Excellence category for its work with PHINIA and in the Transformation category for its work with Carrier. The ISG Paragon Awards recognize enterprise-provider partnerships that leverage technology, innovation, and new operating models to deliver measurable business impact. The recognitions highlight LTM's ability to help global enterprises accelerate transformation through industry expertise, technology innovation, and execution excellence. Carrier: Following significant M&A activities, Carrier, a global leader in intelligent climate and energy solutions, sought to address a fragmented technology landscape, siloed operating functions, and limited visibility into application ownership and costs across its 2,000+ application estate. LTM partnered closely with Carrier
RGI Expands Its Digital Insurance Proposition With the Acquisition of D4Next30.9.2026 11:00:00 EEST | Press release
RGI, the leading provider of digital solutions for the European insurance industry, announces the acquisition of D4Next, an insurance technology company specializing in solutions that connect insurance products, distribution channels and digital processes, powered by innovative AI models. The acquisition broadens RGI’s ability to support insurers in addressing one of the key challenges facing the industry: how to accelerate business and technological innovation while progressively evolving an increasingly complex technology landscape. Supporting the evolution of insurance at the pace of the market As insurers continue to invest in new products, digital channels, distribution models and more intelligent processes, the ability to introduce innovation progressively, and connect new capabilities with the technologies already supporting the business, is becoming increasingly important. With the acquisition of D4Next, RGI expands its proposition with capabilities designed to support this evo
Roquette to Showcase End-to-End Pharma Solutions for Patient-Centric Formulations at CPHI Milan 202630.9.2026 11:00:00 EEST | Press release
Roquette will showcase its end-to-end portfolio of pharmaceutical excipients, drug delivery solutions and leading technical expertise at CPHI Milan 2026 in Italy, where the company will welcome visitors at booth 1A18 in the excipients hall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929017969/en/ Visit Roquette at booth 1A18 in the excipients hall. At this year’s global industry event, Roquette will highlight key product brands supporting formulation performance, patient-centric drug delivery and biopharma innovation, including METHOCEL™ cellulose ethers, PEARLITOL® mannitol, Avicel® microcrystalline cellulose, POLYOX™ polyethylene oxide, KLEPTOSE® cyclodextrins, LYCADEX® pyrogen-free dextrose monohydrate, Qualicaps™ by Roquette hard capsules and its alginate portfolio from sustainably sourced seaweed. The company will also spotlight its biopharma solutions spanning upstream processing, downstream efficiency, and form
SoftBank Robotics Expands AI & Robotics Solutions for Foodservice in EMEA30.9.2026 10:30:00 EEST | Press release
SoftBank Robotics UK Ltd. today announced that it will showcase its AI & Robotics solutions for foodservice at EquipHotel 2026, taking place in Paris, France, from 2 to 5 November 2026, as part of its efforts to expand foodservice automation initiatives across the EMEA region. Hospitality and foodservice operators continue to face operational challenges, including labour shortages, difficulties in recruiting skilled staff, rising costs, inconsistent food quality, and food waste. SoftBank Robotics aims to help address these challenges through robotics and automation, supporting more efficient, consistent and flexible foodservice operations. STEAMA is a steam-based cooking robot that uses high-pressure, high-temperature steam to prepare frozen noodle dishes in about 90 seconds. Designed for simple, one-touch operation, it helps operators consistently serve freshly prepared dishes with ease. FLAMA and BOTINKIT Omni are automated cooking solutions that improve kitchen efficiency and consis
IFF Introduces AQUASCENT™: Advanced Water-Based Fragrance Technology30.9.2026 10:00:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances and health and biosciences, today introduced AQUASCENT™, a new vegan, water-based carrier for fine fragrance. Crafted from a proprietary formula made with biodegradable materials, AQUASCENT™ delivers enhanced olfactive performance and visual clarity for consumers while supporting a more sustainable approach to shipping the product. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929938674/en/ AQUASCENT™ is IFF's new water-based fragrance carrier technology that maintains visual clarity while supporting fragrance loads from 10% to up to 25%, compared with up to 15% for most comparable systems. “AQUASCENT™ reflects our continued investment in new scent technologies and formats that create compelling fragrance experiences while supporting the industry’s growing focus on sustainability,” said Sabrya Meflah, president of Fine Fragrance for IFF Scent. “This technology illus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom